Table V. Studies investigating TLR7/8 agonist admixture formulation/combination vaccination
AdjuvantFormulationModelDisease ModelImmune Response ActivatedReference
Phospholipid-conjugated TLR7 agonistAdmixed with small molecule TLR4 adjuvantMiceInfluenzaCombined TLR4 and TLR7 adjuvant vaccination induces Th1- and Th2-type immune responses for long-lived cellular and neutralizing humoral immunity against the viral HA(75)
3M-052Liposomal and emulsion formulations with GLAMiceEnteric protozoan pathogenEnhancement of intestinal IgA, plasma IgG2a/IgG1, IFN-γ, and IL-17A responses, which inhibited parasites adherence to host cells(76)
R848Admixture and Mincle C-type lectin receptor (CLR) agonistHuman naive T cell stimulation ex vivoN/ADual TLR7/8 and macrophage-inducible CLR activation of human newborn DCs synergistically drove Th1 polarization ex vivo(77)
TLR7 agonist GS-9620 (vesatolimod)Heterologous prime boost vaccination/immunomodulator therapyNHPHIVOral administration of TLR7 agonist in combination with Ad26/MVA prime-boost vaccination decreased levels of viral DNA in LNs and peripheral blood, improving virologic control rebound(78)
  • N/A, not applicable.